Update on Novo Nordisk manufacturing deviation for NovoSeven©, resulting in shortages for NovoEight© and Esperoct©
Mid-June 2024, the European Haemophilia Consortium (EHC), the National Bleeding Disorder Foundation (NBDF) and the World Federation of Hemophilia (WFH) were made aware of a manufacturing deviation in the production line of several products for the treatment of haemophilia and other coagulopathies manufactured by Novo Nordisk in Denmark. This manufacturing deviation resulted in some NovoSeven (1 and 2 mg) vials being potentially underfilled in informed countries and resulted in shortages of Novoseven, NovoEight and Esperoct.